Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;33(4):551-8.
doi: 10.1007/s10571-013-9925-8. Epub 2013 Mar 17.

Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling

Affiliations

Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling

Jason M Conley et al. Cell Mol Neurobiol. 2013 May.

Abstract

Activator of G protein signaling 3 (AGS3) binds Gα(i) subunits in the GDP-bound state, implicating AGS3 as an important regulator of Gα(i)-linked receptor (e.g., D2 dopamine and μ-opioid) signaling. We examined the ability of AGS3 to modulate recombinant adenylyl cyclase (AC) type 1 and 2 signaling in HEK293 cells following both acute and persistent activation of the D(2L) dopamine receptor (D(2L)DR). AGS3 expression modestly enhanced the potency of acute quinpirole-induced D(2L)DR modulation of AC1 or AC2 activity. AGS3 also promoted desensitization of D(2L)DR-mediated inhibition of AC1, whereas desensitization of D(2L)DR-mediated AC2 activation was significantly attenuated. Additionally, AGS3 reduced D(2L)DR-mediated sensitization of AC1 and AC2. These data suggest that AGS3 is involved in altering G protein signaling in a complex fashion that is effector-specific and dependent on the duration of receptor activation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of AGS3 expression on acute regulation of AC isoforms. a Acute inhibition of A23187 (10 μM)-stimulated cAMP accumulation was measured following incubation with quinpirole as indicated in HEK293 cells stably expressing AC1 and the D2LDR, or AC1 and the D2LDR together with AGS3-Venus. b Cyclic AMP accumulation was quantified in HEK293 cells stably expressing AC2 and the D2LDR with or without AGS3-Venus following acute treatment with PMA (1 μM) and increasing concentrations of quinpirole as indicated. Data points represent mean ± S.E.M. of at least three independent experiments performed in duplicate
Fig. 2
Fig. 2
The effect of AGS3 expression on functional desensitization of D2LDR-modulated AC1 activity. HEK293 cells stably expressing AC1, the D2LDR, and AGS3-Venus were treated with quinpirole (1 μM) or vehicle for 2 h, followed by selective AC1 stimulation with A23187 (10 μM) and activation of the D2LDR with quinpirole (1 μM). Data represent the mean ± SEM of three independent experiments
Fig. 3
Fig. 3
The effect of AGS3 expression on functional desensitization of D2LDR-modulated AC2 activity. HEK293 cells stably expressing AC2 and the D2LDR alone, or together with AGS3-Venus or AGS3-Q/A-Venus were treated with quinpirole (1 μM) or vehicle for 2 h, followed by stimulation with PMA (1 μM) and quinpirole (1 μM). Data represent the mean ± SEM of at least three independent experiments. **p < 0.01, compared with AC2 + D2L condition, one way analysis of variance followed by Dunnett’s post hoc test
Fig. 4
Fig. 4
Effect of AGS3 expression on heterologous sensitization of AC isoforms. a HEK293 cells stably expressing AC1 and D2LDR were stimulated with vehicle or quinpirole (1 μM) for 2 h, washed, and subsequently stimulated with A23187 (10 μM) as indicated. Data represent mean ± SEM of three independent experiments. *p < 0.05, unpaired t test. b HEK293 cells stably expressing AC2 and D2LDR in the absence of, or coexpressed with AGS3-Venus or AGS3-Q/A-Venus as indicated were pretreated with vehicle or quinpirole (1 μM) for 2 h, washed, and subsequently stimulated with PMA (1 μM). Data represent mean ± S.E.M. of at least three independent experiments. **p < 0.01, one way analysis of variance followed by Dunnett’s post hoc test

References

    1. An N, Blumer JB, Bernard ML, Lanier SM (2008) The PDZ and band 4.1 containing protein Frmpd1 regulates the subcellular location of activator of G-protein signaling 3 and its interaction with G-proteins. J Biol Chem 283:24718–24728 - DOI - PMC - PubMed
    1. Bernard ML, Peterson YK, Chung P, Jourdan J, Lanier SM (2001) Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins. J Biol Chem 276:1585–1593 - DOI - PubMed
    1. Blumer JB, Chandler LJ, Lanier SM (2002) Expression analysis and subcellular distribution of the two G-protein regulators AGS3 and LGN indicate distinct functionality: localization of LGN to the midbody during cytokinesis. J Biol Chem 277:15897–15903 - DOI - PubMed
    1. Blumer JB, Smrcka AV, Lanier SM (2007) Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling. Pharmacol Ther 113:488–506 - DOI - PMC - PubMed
    1. Bowers MS, McFarland K, Lake RW, Peterson YK, Lapish CC, Gregory ML, Lanier SM, Kalivas PW (2004) Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking. Neuron 42:269–281 - DOI - PMC - PubMed

Publication types

LinkOut - more resources